INNOVAX announces that it will relocate its Headquarter on 18th November 2017.
The new headquarters are located at 1st Floor, 50 Shan Bian Hong East Road, Haicang District, Xiamen, Fujian, China. A new facility set up for manufacturing HPV vaccine is also located here. The vial filling line in the facility can be also used for HEV vaccine.
This new facility is designed according to WHO prequalification requirements, which is built to meet the high-quality production of vaccines for people in need. At the same time, it aims to provide an environmental friendly place for each employee to work and to contribute. The state of art facility is expected to be in full operation by 2019.
The existing place, which is about 4.5km from the new site, will remain in use for the manufacturing of HEV vaccine.
With relocation to the new headquarter, INNOVAX will maintain to hold its mission in developing, manufacturing and marketing innovative vaccines, and continue to practice its commitment: “Increase the availability of high quality innovative vaccines to combat infectious diseases globally.” With this effort, we also believe INNOVAX will be constantly growing.
Our contact information will remain the same.
Xiamen Innovax Biotech Co., Ltd. (INNOVAX) is a leading company in the field of developing, manufacturing and marketing innovative vaccines with its headquarter and manufacture base in Xiamen, China.
In collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD), Innovax has established a core-platform using DNA recombinant technology to express protein in E. coli for vaccine production. Based on this platform, the world’s first Hepatitis E Vaccine, Hecolin? has launched in China in October 2012. In addition, its Cervical Cancer Vaccine–Cecolin? (phase III clinical trial under way) and a Genital Warts Vaccine-Gecolin? (phase I clinical trial completed) have been developed. Furthermore, a 9-valent HPV vaccine is now in application of clinical approval.